Department of Psychiatry, Psychotherapy and Psychosomatics, Zurich University, Hospital for Psychiatry, Lenggstrasse 31, Postfach 1931, CH-8032 Zürich, Switzerland.
J ECT. 2013 Sep;29(3):e33-5. doi: 10.1097/YCT.0b013e31828b34c6.
This report addresses the dilemma of continuing lithium prophylaxis and antidepressant therapy in view of cardiovascular adverse effects under electroconvulsive therapy (ECT) in patients with a long history of recurrent affective disorders. A severely depressed 48-year-old woman who had been treated with lithium for 18 years developed a ventricular tachycardia during ECT. Possible interaction with succinylcholine was taken into account, and rocuronium was used as an alternative muscle relaxant. Electroconvulsive therapy was continued without adverse effects after reduction of lithium and withdrawal from duloxetine. Systemic studies on cardiac adverse effects of serotonin and norepinephrine reuptake inhibitors and serotonin and norepinephrine reuptake inhibitor-lithium combinations during ECT are needed.
本报告针对有反复发作情感障碍病史的患者,在电抽搐治疗(ECT)下考虑到心血管不良影响而继续锂预防和抗抑郁治疗这一困境。一名 48 岁的严重抑郁女性,服用锂已有 18 年,在 ECT 期间发生室性心动过速。考虑到可能与琥珀胆碱相互作用,改用罗库溴铵作为替代肌松剂。在减少锂和停用度洛西汀后,ECT 继续进行,无不良反应。ECT 期间,需要进行关于 5-羟色胺和去甲肾上腺素再摄取抑制剂以及 5-羟色胺和去甲肾上腺素再摄取抑制剂-锂联合治疗的心脏不良影响的系统研究。